OnCo

Forest plot

383 hazard ratios from 258 trials on one axis. A hazard ratio below 1 means the experimental arm did better on that endpoint; the line is the 95% confidence interval. Pick a cancer, a setting and an endpoint to see comparable trials side by side, then download the rows.

Trial · endpoint◀ favours experimental arm · favours control ▶HR (95% CI)0.10.20.30.50.711.5235Hazard ratio (log scale); square area follows participants, shade follows evidence scoreINVICTUSProgression-free survival (primary) · Sarcomas (sof…0.15 (0.09–0.25)n = 129LAURAProgression-free survival (primary) · Non-small-cel…0.16 (0.10–0.24)n = 216ADAURADisease-free survival (primary) · Non-small-cell lu…0.17 (0.11–0.26)n = 470MajesTEC-3Progression-free survival (primary) · Multiple myel…0.17n = 587CROWNProgression-free survival (primary) · Non-small-cel…0.19 (0.13–0.27)n = 296CheckMate 8HWProgression-free survival (primary) · Colorectal ca…0.21n = 303SELECTProgression-free survival (primary) · Thyroid cancer0.21n = 392GLOWProgression-free survival (primary) · Chronic lymph…0.22 (0.13–0.36)n = 211HORIZON-Breast01Progression-free survival (primary) · HER2-positive…0.22n = 366RESONATEProgression-free survival (primary) · Chronic lymph…0.22 (0.15–0.32)n = 391CABINET (Alliance A0216…Progression-free survival (primary) · Neuroendocrin…0.23 (0.12–0.42)n = 298ALINADisease-free survival (primary) · Non-small-cell lu…0.24 (0.13–0.45)n = 231CARTITUDE-4Progression-free survival (primary) · Multiple myel…0.26 (0.18–0.38)n = 419LIBRETTO-531Progression-free survival (primary) · Thyroid cancer0.28n = 291RUBY / ENGOT-EN6 / GOG-…Progression-free survival (primary) · Endometrial c…0.28 (0.16–0.50)n = 494BL-B01D1-307Progression-free survival (primary) · Triple-negati…0.29 (0.22–0.38)n = 418DeFiProgression-free survival (primary) · Sarcomas (sof…0.29 (0.15–0.55)n = 142NRG-GY018 / KEYNOTE-868Progression-free survival (primary) · Endometrial c…0.30 (0.19–0.48)n = 225SOLO-1Progression-free survival (primary) · Ovarian cancer0.30 (0.23–0.41)n = 391NADINAEvent-free survival (primary) · Melanoma0.32n = 423AGILEEvent-free survival (primary) · Acute myeloid leuka…0.33 (0.16–0.69)n = 146DESTINY-Breast03Progression-free survival (primary) · HER2-positive…0.33 (0.26–0.43)n = 524PAOLA-1 / ENGOT-ov25Progression-free survival · Ovarian cancer0.33 (0.25–0.45)n = 806SANET-ep and SANET-pProgression-free survival (primary) · Neuroendocrin…0.33n = 369PROfoundProgression-free survival (primary) · Prostate canc…0.34 (0.25–0.47)n = 245PROMIDOther time-to-event (primary) · Neuroendocrine tumo…0.34 (0.20–0.59)n = 85RADIANT-3 and RADIANT-4Progression-free survival (primary) · Neuroendocrin…0.35 (0.27–0.45)n = 410INVICTUSOverall survival · Sarcomas (soft tissue, bone, GIS…0.36n = 129TRANSFORMEvent-free survival (primary) · Diffuse large B-cel…0.36 (0.24–0.52)n = 184ClarIDHyProgression-free survival (primary) · Biliary tract…0.37 (0.25–0.54)n = 187CABINET (Alliance A0216…Progression-free survival (primary) · Neuroendocrin…0.38 (0.25–0.59)n = 298evERAProgression-free survival (primary) · HR-positive /…0.38 (0.27–0.54)n = 320ARCHESProgression-free survival (primary) · Prostate canc…0.39 (0.30–0.50)n = 1,150CLEAR (KEYNOTE-581)Progression-free survival (primary) · Renal cell ca…0.39 (0.32–0.49)n = 712COG AALL1731Disease-free survival (primary) · Acute lymphoblast…0.39 (0.24–0.64)n = 1,440INDIGOProgression-free survival (primary) · Glioma & glio…0.39 (0.27–0.56)n = 331CLL14Progression-free survival (primary) · Chronic lymph…0.40n = 432EV-303 / KEYNOTE-905Event-free survival (primary) · Bladder & urothelia…0.40 (0.28–0.56)n = 344RASolute 302Overall survival (primary) · Pancreatic ductal aden…0.40n = 460VISIONProgression-free survival (primary) · Prostate canc…0.40 (0.29–0.57)n = 831ZUMA-7Event-free survival (primary) · Diffuse large B-cel…0.40 (0.31–0.51)n = 359ASCENTProgression-free survival (primary) · Triple-negati…0.41 (0.32–0.52)n = 468DREAMM-7Progression-free survival (primary) · Multiple myel…0.41 (0.31–0.53)n = 494ECOG-ACRIN E1910Overall survival (primary) · Acute lymphoblastic le…0.41 (0.23–0.73)n = 224PSMAforeProgression-free survival (primary) · Prostate canc…0.41 (0.29–0.56)n = 468ALASCCAOther time-to-event · Colorectal cancer0.42 (0.21–0.83)n = 626CheckMate 067Progression-free survival (primary) · Melanoma0.42n = 945DUO-E / GOG-3041 / ENGO…Progression-free survival · Endometrial cancer0.42 (0.22–0.80)n = 718EMBARKMetastasis-free survival (primary) · Prostate cancer0.42 (0.30–0.61)n = 713PERSEUSProgression-free survival (primary) · Multiple myel…0.42 (0.30–0.59)n = 709SEQUOIAProgression-free survival (primary) · Chronic lymph…0.42 (0.28–0.63)n = 479INAVO120Progression-free survival (primary) · HR-positive /…0.43 (0.32–0.59)n = 325PRIMA / ENGOT-OV26Progression-free survival (primary) · Ovarian cancer0.43 (0.31–0.59)n = 733AGILEOverall survival · Acute myeloid leukaemia0.44 (0.27–0.73)n = 146BREAKWATERProgression-free survival · Colorectal cancer0.44CELESTIALProgression-free survival · Hepatocellular carcinoma0.44n = 707SERENA-6Progression-free survival (primary) · HR-positive /…0.44 (0.31–0.60)n = 315EV-302 / KEYNOTE-A39Progression-free survival (primary) · Bladder & uro…0.45 (0.38–0.54)n = 886SSGXVIII/AIO (adjuvant…Overall survival · Sarcomas (soft tissue, bone, GIS…0.45n = 400SWOG S1826Progression-free survival (primary) · Hodgkin lymph…0.45 (0.30–0.65)n = 976DESTINY-Breast04Progression-free survival · HR-positive / HER2-nega…0.46 (0.24–0.89)n = 58LIBRETTO-431Progression-free survival (primary) · Non-small-cel…0.46 (0.31–0.70)n = 212SSGXVIII/AIO (adjuvant…Disease-free survival (primary) · Sarcomas (soft ti…0.46 (0.32–0.65)n = 397CLARINETProgression-free survival (primary) · Neuroendocrin…0.47 (0.30–0.73)n = 204DESTINY-Breast05Disease-free survival (primary) · HER2-positive bre…0.47 (0.34–0.66)n = 1,635EV-302 / KEYNOTE-A39Overall survival (primary) · Bladder & urothelial c…0.47 (0.38–0.58)n = 886ASCENTOverall survival · Triple-negative breast cancer (T…0.48 (0.38–0.59)n = 529NMTRC003/003B (DFMO mai…Event-free survival (primary) · Neuroblastoma (paed…0.48 (0.27–0.85)n = 360RADIANT-3 and RADIANT-4Progression-free survival (primary) · Neuroendocrin…0.48 (0.35–0.67)n = 302ADAURAOverall survival · Non-small-cell lung cancer0.49 (0.33–0.73)n = 682ADAURAOverall survival · Non-small-cell lung cancer0.49 (0.34–0.70)n = 682ALASCCAOther time-to-event (primary) · Colorectal cancer0.49 (0.24–0.98)n = 626BREAKWATEROverall survival · Colorectal cancer0.49ClarIDHyOverall survival · Biliary tract cancer (cholangioc…0.49n = 187CodeBreaK 300Progression-free survival (primary) · Colorectal ca…0.49 (0.30–0.80)n = 107KarMMa-3Progression-free survival (primary) · Multiple myel…0.49 (0.38–0.65)n = 386SANET-ep and SANET-pProgression-free survival (primary) · Neuroendocrin…0.49n = 369ATOMIC (Alliance A02150…Disease-free survival (primary) · Colorectal cancer0.50 (0.34–0.72)n = 712CAPItello-291Progression-free survival (primary) · HR-positive /…0.50 (0.38–0.65)n = 289EV-303 / KEYNOTE-905Overall survival · Bladder & urothelial cancer0.50 (0.33–0.74)n = 344KATHERINEDisease-free survival (primary) · HER2-positive bre…0.50 (0.39–0.64)n = 1,486CheckMate 9ERProgression-free survival (primary) · Renal cell ca…0.51 (0.41–0.64)n = 651DESTINY-Breast04Progression-free survival (primary) · HR-positive /…0.51 (0.40–0.64)n = 494HARMONi-2Progression-free survival (primary) · Non-small-cel…0.51 (0.38–0.69)n = 398IMCgp100-202Overall survival (primary) · Melanoma0.51n = 378ATHENA-MONO / GOG-3020Progression-free survival (primary) · Ovarian cancer0.52 (0.40–0.68)n = 538CARES-310Progression-free survival (primary) · Hepatocellula…0.52n = 543DREAMM-8Progression-free survival (primary) · Multiple myel…0.52 (0.37–0.73)n = 302JUPITER-02Progression-free survival (primary) · Head and neck…0.52n = 289PACIFICProgression-free survival (primary) · Non-small-cel…0.52 (0.42–0.65)n = 713MAGNITUDEProgression-free survival (primary) · Prostate canc…0.53 (0.36–0.79)n = 225POLOProgression-free survival (primary) · Pancreatic du…0.53 (0.35–0.82)n = 154CheckMate 648Overall survival (primary) · Oesophageal cancer0.54n = 970COLUMBUSProgression-free survival (primary) · Melanoma0.54n = 577HER2CLIMBProgression-free survival (primary) · HER2-positive…0.54 (0.42–0.71)n = 480IMforteProgression-free survival (primary) · Small-cell lu…0.54 (0.43–0.67)n = 483MONARCH 3Progression-free survival (primary) · HR-positive /…0.54 (0.42–0.70)n = 493NRG-GY018 / KEYNOTE-868Progression-free survival (primary) · Endometrial c…0.54 (0.41–0.71)n = 588CARTITUDE-4Overall survival · Multiple myeloma0.55 (0.39–0.79)n = 419EMERALDProgression-free survival (primary) · HR-positive /…0.55 (0.39–0.77)n = 228SOLO-1Overall survival · Ovarian cancer0.55 (0.40–0.76)n = 391ALFA-0701Event-free survival (primary) · Acute myeloid leuka…0.56 (0.42–0.76)n = 271DESTINY-Breast09Progression-free survival (primary) · HER2-positive…0.56 (0.44–0.71)n = 770evERAProgression-free survival (primary) · HR-positive /…0.56 (0.44–0.71)n = 320KEYNOTE-775 / Study 309Progression-free survival (primary) · Endometrial c…0.56 (0.47–0.66)n = 827PALOMA-2Progression-free survival (primary) · HR-positive /…0.56 (0.46–0.69)n = 666AETHERAProgression-free survival (primary) · Hodgkin lymph…0.57 (0.40–0.81)n = 329CEPHEUSProgression-free survival · Multiple myeloma0.57 (0.41–0.79)n = 395DUO-E / GOG-3041 / ENGO…Progression-free survival · Endometrial cancer0.57 (0.44–0.73)n = 718MONALEESA-2Progression-free survival (primary) · HR-positive /…0.57 (0.46–0.70)n = 668TROPION-Breast02Progression-free survival (primary) · Triple-negati…0.57 (0.47–0.69)n = 644VERITAC-2Progression-free survival (primary) · HR-positive /…0.57 (0.42–0.77)n = 270BRUIN CLL-321Progression-free survival (primary) · Chronic lymph…0.58n = 238DREAMM-7Overall survival · Multiple myeloma0.58 (0.43–0.79)n = 494KRYSTAL-12Progression-free survival (primary) · Non-small-cel…0.58 (0.45–0.76)n = 453OlympiADisease-free survival (primary) · Triple-negative b…0.58 (0.41–0.82)n = 1,836PRODIGE 24 / CCTG PA6Disease-free survival (primary) · Pancreatic ductal…0.58 (0.46–0.73)n = 493SHARPOther time-to-event · Hepatocellular carcinoma0.58n = 602SWOG S1801Event-free survival (primary) · Melanoma0.58n = 313DECISIONProgression-free survival (primary) · Thyroid cancer0.59n = 417ECHELON-1Overall survival · Hodgkin lymphoma0.59 (0.40–0.88)n = 1,334EMBER-3Progression-free survival (primary) · HR-positive /…0.59 (0.46–0.75)n = 426IMvigor011Overall survival · Bladder & urothelial cancer0.59 (0.41–0.86)n = 761KEYNOTE-671Event-free survival (primary) · Non-small-cell lung…0.59 (0.48–0.72)n = 797PSMAforeOverall survival · Prostate cancer0.59n = 468BL-B01D1-307Overall survival (primary) · Triple-negative breast…0.60 (0.42–0.85)n = 418CAPItello-291Progression-free survival (primary) · HR-positive /…0.60 (0.51–0.71)n = 708DeLLphi-304Overall survival (primary) · Small-cell lung cancer0.60 (0.47–0.77)n = 509HERA, NSABP B-31 & NCCT…Disease-free survival (primary) · HER2-positive bre…0.60 (0.53–0.68)n = 9,000IMROZProgression-free survival (primary) · Multiple myel…0.60 (0.41–0.88)n = 446INTERLACEOverall survival (primary) · Cervical cancer0.60 (0.40–0.91)n = 500KEYNOTE-024 & KEYNOTE-1…Overall survival (primary) · Non-small-cell lung ca…0.60 (0.50–0.72)n = 616KEYNOTE-177Progression-free survival (primary) · Colorectal ca…0.60 (0.45–0.80)n = 307KEYNOTE-826Overall survival (primary) · Cervical cancer0.60 (0.49–0.74)n = 617RxPONDER (SWOG S1007)Disease-free survival (primary) · HR-positive / HER…0.60 (0.43–0.83)n = 5,083STAMPEDEOverall survival (primary) · Prostate cancer0.60 (0.50–0.71)n = 11,992CHAARTED (E3805)Overall survival (primary) · Prostate cancer0.61 (0.47–0.80)n = 790FORTITUDE-101Overall survival (primary) · Gastric & gastro-oesop…0.61n = 547KEYNOTE-048Overall survival (primary) · Head and neck squamous…0.61n = 882SUNLIGHTOverall survival (primary) · Colorectal cancer0.61 (0.49–0.77)n = 492ASCENT-03Progression-free survival (primary) · Triple-negati…0.62 (0.50–0.77)n = 558BEATcc / ENGOT-Cx10 / G…Progression-free survival (primary) · Cervical canc…0.62 (0.49–0.78)n = 410CARES-310Overall survival (primary) · Hepatocellular carcino…0.62n = 543CheckMate 8HWProgression-free survival · Colorectal cancer0.62n = 582COMPASSION-16 / AK104-3…Progression-free survival (primary) · Cervical canc…0.62 (0.49–0.80)n = 445DESTINY-Breast06Progression-free survival (primary) · HR-positive /…0.62 (0.51–0.74)n = 713ELEVATE-TNOverall survival · Chronic lymphocytic leukaemia0.62n = 535EMBER-3Progression-free survival (primary) · HR-positive /…0.62 (0.46–0.82)n = 874FLAURA2Progression-free survival (primary) · Non-small-cel…0.62 (0.49–0.79)n = 557IMpassion130Progression-free survival (primary) · Triple-negati…0.62 (0.49–0.78)n = 369KEYNOTE-024 & KEYNOTE-1…Overall survival (primary) · Non-small-cell lung ca…0.62 (0.48–0.81)n = 305KEYNOTE-564Overall survival · Renal cell carcinoma0.62 (0.44–0.87)n = 994KEYNOTE-775 / Study 309Overall survival (primary) · Endometrial cancer0.62 (0.51–0.75)n = 827PAOLA-1 / ENGOT-ov25Overall survival · Ovarian cancer0.62 (0.45–0.85)n = 806PRIMA / ENGOT-OV26Progression-free survival (primary) · Ovarian cancer0.62 (0.50–0.76)n = 733STARGLOOverall survival (primary) · Diffuse large B-cell l…0.62 (0.43–0.88)n = 274VISIONOverall survival (primary) · Prostate cancer0.62 (0.52–0.74)n = 831ASTRUM-005Overall survival (primary) · Small-cell lung cancer0.63 (0.49–0.82)n = 585CHALLENGE (CCTG CO.21)Overall survival · Colorectal cancer0.63 (0.43–0.94)n = 889CheckMate 816Event-free survival (primary) · Non-small-cell lung…0.63 (0.43–0.91)n = 358DESTINY-Breast06Progression-free survival · HR-positive / HER2-nega…0.63 (0.53–0.75)n = 866DUO-O / ENGOT-ov46Progression-free survival (primary) · Ovarian cancer0.63 (0.52–0.76)n = 1,130EF-14Progression-free survival (primary) · Glioma & glio…0.63 (0.52–0.76)n = 695EF-14Overall survival · Glioma & glioblastoma0.63 (0.53–0.76)n = 695EORTC 26981 / NCIC CE.3…Overall survival (primary) · Glioma & glioblastoma0.63 (0.52–0.75)n = 573HERA, NSABP B-31 & NCCT…Overall survival · HER2-positive breast cancer0.63 (0.54–0.73)n = 4,046KEYNOTE-826Overall survival (primary) · Cervical cancer0.63 (0.52–0.77)n = 617RESORCEOverall survival (primary) · Hepatocellular carcino…0.63 (0.50–0.79)n = 573TALAPRO-2Progression-free survival (primary) · Prostate canc…0.63 (0.51–0.78)n = 805TROPION-Breast01Progression-free survival (primary) · HR-positive /…0.63 (0.52–0.76)n = 732TROPION-Lung01Progression-free survival · Non-small-cell lung can…0.63 (0.51–0.79)n = 604ABC-02Overall survival (primary) · Biliary tract cancer (…0.64 (0.52–0.80)n = 410ACE-Breast-02Progression-free survival (primary) · HER2-positive…0.64n = 441ADMIRALOverall survival (primary) · Acute myeloid leukaemia0.64 (0.49–0.83)n = 371CheckMate 648Overall survival · Oesophageal cancer0.64n = 970COMPASSION-16 / AK104-3…Overall survival (primary) · Cervical cancer0.64 (0.48–0.86)n = 445DESTINY-Breast04Overall survival · HR-positive / HER2-negative brea…0.64 (0.49–0.84)n = 557IMvigor011Disease-free survival (primary) · Bladder & urothel…0.64 (0.47–0.88)n = 250THOROverall survival (primary) · Bladder & urothelial c…0.64 (0.47–0.88)n = 266HER2CLIMB-05Progression-free survival (primary) · HER2-positive…0.64n = 654ALPINEProgression-free survival (primary) · Chronic lymph…0.65 (0.49–0.86)n = 652AMPLIFYProgression-free survival · Chronic lymphocytic leu…0.65 (0.49–0.87)n = 867ASCENT-04 / KEYNOTE-D19Progression-free survival (primary) · Triple-negati…0.65 (0.51–0.84)n = 443IMbrave150Progression-free survival (primary) · Hepatocellula…0.65n = 501INTERLACEProgression-free survival (primary) · Cervical canc…0.65 (0.46–0.91)n = 500KEYNOTE-204Progression-free survival (primary) · Hodgkin lymph…0.65 (0.48–0.88)n = 304KEYNOTE-522Event-free survival (primary) · Triple-negative bre…0.65 (0.51–0.83)n = 1,174KEYNOTE-859Overall survival · Gastric & gastro-oesophageal jun…0.65 (0.53–0.79)n = 1,579MIRASOL / GOG-3045Progression-free survival (primary) · Ovarian cancer0.65 (0.52–0.81)n = 453SOLAR-1Progression-free survival (primary) · HR-positive /…0.65 (0.50–0.85)n = 341ARCHESOverall survival · Prostate cancer0.66 (0.53–0.81)n = 1,150CodeBreaK 200Progression-free survival (primary) · Non-small-cel…0.66 (0.51–0.86)n = 345FRESCO-2Overall survival (primary) · Colorectal cancer0.66 (0.55–0.80)n = 691GHSG HD21Progression-free survival (primary) · Hodgkin lymph…0.66 (0.45–0.97)n = 1,482HER2CLIMBOverall survival · HER2-positive breast cancer0.66 (0.50–0.88)n = 612IMbrave150Overall survival (primary) · Hepatocellular carcino…0.66 (0.52–0.85)n = 501KATHERINEOverall survival · HER2-positive breast cancer0.66 (0.51–0.87)n = 1,486KEYNOTE-355Progression-free survival (primary) · Triple-negati…0.66 (0.50–0.88)n = 847KEYNOTE-522Overall survival · Triple-negative breast cancer (T…0.66 (0.50–0.87)n = 1,174LATITUDEOverall survival (primary) · Prostate cancer0.66 (0.56–0.78)n = 1,199LEAP-012Progression-free survival (primary) · Hepatocellula…0.66n = 480PROpelProgression-free survival (primary) · Prostate canc…0.66 (0.54–0.81)n = 796RATIONALE-306Overall survival (primary) · Oesophageal cancer0.66n = 649REFLECTProgression-free survival · Hepatocellular carcinoma0.66n = 954TROPiCS-02Progression-free survival (primary) · HR-positive /…0.66 (0.53–0.83)n = 543VIALE-AOverall survival (primary) · Acute myeloid leukaemia0.66 (0.52–0.85)n = 431COMPETEProgression-free survival (primary) · Neuroendocrin…0.67 (0.48–0.95)n = 309IMpassion130Overall survival · Triple-negative breast cancer (T…0.67 (0.53–0.86)n = 902INAVO120Overall survival · HR-positive / HER2-negative brea…0.67 (0.48–0.94)n = 325innovaTV 301 / ENGOT-cx…Progression-free survival · Cervical cancer0.67 (0.54–0.82)n = 502KEYNOTE-A18 / ENGOT-cx1…Overall survival (primary) · Cervical cancer0.67 (0.50–0.90)n = 1,060MIRASOL / GOG-3045Overall survival · Ovarian cancer0.67 (0.50–0.89)n = 453OVHIPEC-1Overall survival · Ovarian cancer0.67 (0.48–0.94)n = 245monarchEOther time-to-event · HR-positive / HER2-negative b…0.68n = 5,637ARASENSOverall survival (primary) · Prostate cancer0.68 (0.57–0.80)n = 1,306BEATcc / ENGOT-Cx10 / G…Overall survival (primary) · Cervical cancer0.68 (0.52–0.88)n = 410CLEOPATRAProgression-free survival (primary) · HER2-positive…0.68 (0.58–0.80)n = 808CROSSOverall survival (primary) · Oesophageal cancer0.68n = 366monarchEDisease-free survival · HR-positive / HER2-negative…0.68 (0.60–0.77)n = 5,637NIAGARAEvent-free survival (primary) · Bladder & urothelia…0.68 (0.56–0.82)n = 1,063OlympiAOverall survival · Triple-negative breast cancer (T…0.68 (0.47–0.97)n = 1,836POTOMACDisease-free survival (primary) · Bladder & urothel…0.68 (0.50–0.93)n = 1,018PRODIGE 24 / CCTG PA6Overall survival · Pancreatic ductal adenocarcinoma0.68n = 493CheckMate 214Overall survival (primary) · Renal cell carcinoma0.69 (0.59–0.81)n = 847CheckMate 577Disease-free survival (primary) · Oesophageal cance…0.69n = 794CLEOPATRAOverall survival · HER2-positive breast cancer0.69 (0.58–0.82)n = 808CPX-351 Study 301Overall survival (primary) · Acute myeloid leukaemia0.69 (0.52–0.90)n = 309EMPOWER-Cervical 1 / GO…Overall survival (primary) · Cervical cancer0.69 (0.56–0.84)n = 608JAVELIN Bladder 100Overall survival (primary) · Bladder & urothelial c…0.69 (0.56–0.86)n = 700KEYNOTE-426Progression-free survival (primary) · Renal cell ca…0.69n = 861PROfoundOverall survival · Prostate cancer0.69 (0.50–0.97)n = 387ROSELLA / GOG-3073Overall survival · Ovarian cancer0.69n = 381RUBY / ENGOT-EN6 / GOG-…Overall survival (primary) · Endometrial cancer0.69 (0.54–0.89)n = 494SHARPOverall survival (primary) · Hepatocellular carcino…0.69 (0.55–0.87)n = 602ALSYMPCAOverall survival (primary) · Prostate cancer0.70 (0.58–0.83)n = 921CheckMate 141Overall survival (primary) · Head and neck squamous…0.70n = 361CheckMate 274Disease-free survival (primary) · Bladder & urothel…0.70 (0.57–0.85)n = 709DESTINY-Gastric04Overall survival (primary) · Gastric & gastro-oesop…0.70n = 494EMERALDProgression-free survival (primary) · HR-positive /…0.70 (0.55–0.88)n = 478EMERALD-3Progression-free survival (primary) · Hepatocellula…0.70n = 725ESCORT-1stOverall survival (primary) · Oesophageal cancer0.70n = 596IMpower133Overall survival (primary) · Small-cell lung cancer0.70 (0.54–0.91)n = 403innovaTV 301 / ENGOT-cx…Overall survival (primary) · Cervical cancer0.70 (0.54–0.89)n = 502KEYNOTE-A18 / ENGOT-cx1…Progression-free survival (primary) · Cervical canc…0.70 (0.55–0.89)n = 1,060lidERADisease-free survival (primary) · HR-positive / HER…0.70n = 4,200MARIPOSAProgression-free survival (primary) · Non-small-cel…0.70 (0.58–0.85)n = 858PORTEC-3Overall survival · Endometrial cancer0.70 (0.51–0.97)n = 660ROSELLA / GOG-3073Progression-free survival (primary) · Ovarian cancer0.70 (0.54–0.91)n = 381CheckMate 649Overall survival (primary) · Gastric & gastro-oesop…0.71 (0.61–0.81)n = 955DeLLphi-304Progression-free survival · Small-cell lung cancer0.71 (0.59–0.86)n = 509Euro Ewing 2012Event-free survival (primary) · Sarcomas (soft tiss…0.71 (0.55–0.92)n = 640MATTERHORNEvent-free survival (primary) · Gastric & gastro-oe…0.71n = 948SPLASHProgression-free survival (primary) · Prostate canc…0.71 (0.55–0.92)n = 412TOWEROverall survival (primary) · Acute lymphoblastic le…0.71 (0.55–0.93)n = 405NATALEEDisease-free survival · HR-positive / HER2-negative…0.71 (0.61–0.84)n = 5,101CHALLENGE (CCTG CO.21)Disease-free survival (primary) · Colorectal cancer0.72 (0.55–0.94)n = 889CheckMate 214Overall survival · Renal cell carcinoma0.72 (0.62–0.83)n = 1,096CheckMate 816Overall survival · Non-small-cell lung cancer0.72 (0.52–0.99)n = 358GOG-0218 & ICON7 (bevac…Progression-free survival (primary) · Ovarian cancer0.72 (0.63–0.82)n = 3,401IMbrave050Disease-free survival (primary) · Hepatocellular ca…0.72 (0.56–0.93)n = 668KEYNOTE-564Disease-free survival (primary) · Renal cell carcin…0.72 (0.59–0.87)n = 994KEYNOTE-590Overall survival · Oesophageal cancer0.72 (0.62–0.84)n = 749KEYNOTE-671Overall survival (primary) · Non-small-cell lung ca…0.72 (0.56–0.93)n = 797KEYNOTE-B96 / ENGOT-ov65Progression-free survival (primary) · Ovarian cancer0.72 (0.58–0.89)OlympiAOverall survival · Triple-negative breast cancer (T…0.72 (0.56–0.93)n = 1,836PACIFICOverall survival (primary) · Non-small-cell lung ca…0.72 (0.59–0.89)n = 713PSMAdditionProgression-free survival (primary) · Prostate canc…0.72 (0.58–0.89)n = 1,144ADRIATICOverall survival (primary) · Small-cell lung cancer0.73 (0.57–0.93)n = 530CASPIANOverall survival (primary) · Small-cell lung cancer0.73 (0.59–0.91)n = 537COSMIC-313Progression-free survival (primary) · Renal cell ca…0.73 (0.57–0.94)n = 855DESTINY-Breast03Overall survival · HER2-positive breast cancer0.73 (0.56–0.94)n = 524IMforteOverall survival (primary) · Small-cell lung cancer0.73 (0.57–0.95)n = 483KEYNOTE-177Overall survival · Colorectal cancer0.73n = 307KEYNOTE-355Overall survival (primary) · Triple-negative breast…0.73 (0.55–0.95)n = 323KEYNOTE-590Overall survival (primary) · Oesophageal cancer0.73n = 749POLARIXProgression-free survival (primary) · Diffuse large…0.73 (0.57–0.95)n = 879postMONARCHProgression-free survival (primary) · HR-positive /…0.73 (0.57–0.95)n = 368PREOPANC-1 / PREOPANC-2Overall survival (primary) · Pancreatic ductal aden…0.73 (0.56–0.96)n = 246ZUMA-7Overall survival · Diffuse large B-cell lymphoma0.73 (0.54–0.98)n = 359CheckMate 743Overall survival (primary) · Mesothelioma0.74 (0.60–0.91)n = 605CheckMate 743Overall survival · Mesothelioma0.74 (0.62–0.88)n = 605EPCORE DLBCL-1Progression-free survival · Diffuse large B-cell ly…0.74 (0.60–0.92)n = 552ToGAOverall survival (primary) · Gastric & gastro-oesop…0.74 (0.60–0.91)n = 584DESKTOP III / ENGOT-ov20Overall survival (primary) · Ovarian cancer0.75 (0.59–0.96)n = 407frontMINDProgression-free survival (primary) · Diffuse large…0.75n = 899LITESPARK-005Progression-free survival (primary) · Renal cell ca…0.75 (0.63–0.90)n = 746MARIPOSAOverall survival · Non-small-cell lung cancer0.75 (0.61–0.92)n = 1,074monarchEDisease-free survival (primary) · HR-positive / HER…0.75 (0.60–0.93)n = 5,637NATALEEDisease-free survival (primary) · HR-positive / HER…0.75 (0.62–0.91)n = 5,101NIAGARAOverall survival · Bladder & urothelial cancer0.75 (0.59–0.93)n = 1,063PEACE-1Overall survival (primary) · Prostate cancer0.75 (0.59–0.95)n = 1,173RELATIVITY-047Progression-free survival (primary) · Melanoma0.75n = 714TROPION-Lung01Progression-free survival (primary) · Non-small-cel…0.75 (0.62–0.91)n = 604ADRIATICProgression-free survival (primary) · Small-cell lu…0.76 (0.61–0.95)n = 730CELESTIALOverall survival (primary) · Hepatocellular carcino…0.76 (0.63–0.92)n = 707HER2CLIMB-02Progression-free survival (primary) · HER2-positive…0.76 (0.61–0.95)n = 463HIMALAYAOverall survival · Hepatocellular carcinoma0.76n = 1,171KEYNOTE-B96 / ENGOT-ov65Overall survival · Ovarian cancer0.76 (0.61–0.94)MONALEESA-2Overall survival · HR-positive / HER2-negative brea…0.76 (0.63–0.93)n = 668STAMPEDEOverall survival · Prostate cancer0.76n = 11,992TOPAZ-1Overall survival (primary) · Biliary tract cancer (…0.76 (0.64–0.91)n = 685CheckMate 9EROverall survival · Renal cell carcinoma0.77 (0.63–0.95)n = 651ECHELON-1Progression-free survival (primary) · Hodgkin lymph…0.77 (0.60–0.98)n = 1,334EMERALD-1Progression-free survival (primary) · Hepatocellula…0.77 (0.61–0.98)n = 616FLAURA2Overall survival · Non-small-cell lung cancer0.77 (0.61–0.96)n = 557HERTHENA-Lung02Progression-free survival (primary) · Non-small-cel…0.77 (0.63–0.94)n = 586IMpower133Progression-free survival (primary) · Small-cell lu…0.77 (0.62–0.96)n = 403INO-VATE ALLOverall survival (primary) · Acute lymphoblastic le…0.77 (0.58–1.03)n = 326KEYNOTE-048Overall survival (primary) · Head and neck squamous…0.77n = 882MAPSOverall survival (primary) · Mesothelioma0.77 (0.62–0.95)n = 448POLARIXProgression-free survival · Diffuse large B-cell ly…0.77 (0.62–0.97)n = 879QuANTUM-FirstOverall survival (primary) · Acute myeloid leukaemia0.78 (0.61–0.98)n = 539APHINITYDisease-free survival (primary) · HER2-positive bre…0.78 (0.66–0.92)n = 4,805COMPETEOverall survival · Neuroendocrine tumours0.78 (0.50–1.1)n = 309HIMALAYAOverall survival (primary) · Hepatocellular carcino…0.78 (0.66–0.92)n = 782KEYNOTE-859Overall survival (primary) · Gastric & gastro-oesop…0.78 (0.70–0.87)n = 1,579MATTERHORNOverall survival · Gastric & gastro-oesophageal jun…0.78 (0.63–0.96)n = 948RATIFY (CALGB 10603)Overall survival (primary) · Acute myeloid leukaemia0.78 (0.63–0.96)n = 717CheckMate 9DWOverall survival (primary) · Hepatocellular carcino…0.79 (0.65–0.96)n = 668CLEAR (KEYNOTE-581)Overall survival · Renal cell carcinoma0.79 (0.63–0.99)n = 1,069IND.227 / KEYNOTE-483Overall survival (primary) · Mesothelioma0.79 (0.64–0.98)n = 440SOFT & TEXTDisease-free survival (primary) · HR-positive / HER…0.79 (0.70–0.90)n = 5,738TROPiCS-02Overall survival · HR-positive / HER2-negative brea…0.79 (0.65–0.96)n = 543TROPION-Breast02Overall survival (primary) · Triple-negative breast…0.79 (0.64–0.98)n = 644CRYSTAL & FIRE-3Overall survival · Colorectal cancer0.80EMERALD-1Overall survival · Hepatocellular carcinoma0.80 (0.57–1.11)n = 616EXTREMEOverall survival (primary) · Head and neck squamous…0.80n = 442MONARCH 3Overall survival · HR-positive / HER2-negative brea…0.80 (0.62–1.03)n = 493TALAPRO-2Overall survival · Prostate cancer0.80 (0.66–0.96)n = 805BILCAPOverall survival (primary) · Biliary tract cancer (…0.81 (0.63–1.04)n = 447CAPItello-281Progression-free survival (primary) · Prostate canc…0.81 (0.68–0.96)n = 1,012PROpelOverall survival · Prostate cancer0.81 (0.67–1)n = 796RAINBOWOverall survival (primary) · Gastric & gastro-oesop…0.81n = 665IMpassion131Progression-free survival (primary) · Triple-negati…0.82 (0.60–1.12)n = 292KEYNOTE-B96 / ENGOT-ov65Overall survival · Ovarian cancer0.82 (0.69–0.97)PANOVA-3Overall survival (primary) · Pancreatic ductal aden…0.82 (0.68–0.99)n = 571PARADIGMOverall survival (primary) · Colorectal cancer0.82 (0.68–0.99)n = 823CheckMate 274Overall survival · Bladder & urothelial cancer0.83n = 709KEYNOTE-966Overall survival (primary) · Biliary tract cancer (…0.83 (0.72–0.95)n = 1,069NAPOLI 3Overall survival (primary) · Pancreatic ductal aden…0.83 (0.70–0.99)n = 770POLOOverall survival · Pancreatic ductal adenocarcinoma0.83n = 154VERITAC-2Progression-free survival (primary) · HR-positive /…0.83 (0.68–1.02)n = 624KEYNOTE-426Overall survival (primary) · Renal cell carcinoma0.84 (0.71–0.99)n = 861LEAP-002Overall survival (primary) · Hepatocellular carcino…0.84 (0.71–1)n = 794CheckMate 577Overall survival · Oesophageal cancer, Gastric & ga…0.85 (0.70–1.04)n = 794POLARIXOverall survival · Diffuse large B-cell lymphoma0.85 (0.63–1.15)n = 879KEYNOTE-355Overall survival · Triple-negative breast cancer (T…0.86 (0.72–1.04)n = 847IMpassion130Overall survival · Triple-negative breast cancer (T…0.87 (0.75–1.02)n = 902OUTBACK / ANZGOG 0902 /…Overall survival (primary) · Cervical cancer0.91 (0.70–1.18)n = 919REFLECTOverall survival (primary) · Hepatocellular carcino…0.92 (0.79–1.06)n = 954TROPION-Lung01Overall survival (primary) · Non-small-cell lung ca…0.94 (0.78–1.14)n = 604EPCORE DLBCL-1Overall survival (primary) · Diffuse large B-cell l…0.96 (0.77–1.2)n = 552PALLAS & PENELOPE-BDisease-free survival (primary) · HR-positive / HER…0.96 (0.81–1.14)n = 6,862PALOMA-2Overall survival · HR-positive / HER2-negative brea…0.96 (0.78–1.18)n = 666VITAL (VITamin D and Om…Other time-to-event (primary) · 0.96 (0.88–1.06)n = 25,871WHEL (Women's Healthy E…Other time-to-event (primary) · HR-positive / HER2-…0.96 (0.80–1.14)n = 3,088ATLANTISOverall survival (primary) · Small-cell lung cancer0.97 (0.82–1.15)n = 613TheraP (ANZUP 1603)Overall survival · Prostate cancer0.97n = 200HERTHENA-Lung02Overall survival · Non-small-cell lung cancer0.98 (0.79–1.22)n = 586LEAP-012Overall survival (primary) · Hepatocellular carcino…0.98n = 480ACT IVOverall survival (primary) · Glioma & glioblastoma1.01 (0.79–1.3)n = 745CodeBreaK 200Overall survival · Non-small-cell lung cancer1.01n = 345LUME-MesoProgression-free survival (primary) · Mesothelioma1.01 (0.79–1.3)n = 458TROPION-Breast01Overall survival (primary) · HR-positive / HER2-neg…1.01 (0.83–1.22)n = 732COSMIC-313Overall survival · Renal cell carcinoma1.02 (0.85–1.23)n = 855RxPONDER (SWOG S1007)Disease-free survival (primary) · HR-positive / HER…1.02n = 5,083CONTACT-03Progression-free survival (primary) · Renal cell ca…1.03 (0.83–1.28)n = 522VITAL (VITamin D and Om…Other time-to-event (primary) · 1.03 (0.93–1.13)n = 25,871ANNOUNCEOverall survival (primary) · Sarcomas (soft tissue,…1.05 (0.84–1.3)n = 509BELINDAEvent-free survival (primary) · Diffuse large B-cel…1.07 (0.82–1.4)n = 322PERSEPHONEDisease-free survival (primary) · HER2-positive bre…1.07 (0.93–1.24)n = 4,088TAILORxDisease-free survival (primary) · HR-positive / HER…1.08 (0.94–1.24)n = 6,711CheckMate 548 & CheckMa…Overall survival (primary) · Glioma & glioblastoma1.1 (0.92–1.32)n = 716TiNivo-2Progression-free survival (primary) · Renal cell ca…1.1 (0.84–1.43)n = 343IMpassion131Overall survival · Triple-negative breast cancer (T…1.11 (0.76–1.64)n = 651SPLASHOverall survival · Prostate cancer1.11n = 412SANOOverall survival (primary) · Oesophageal cancer1.14 (0.74–1.78)n = 274SARAH and SIRveNIBOverall survival (primary) · Hepatocellular carcino…1.15n = 459CONVERTOverall survival (primary) · Small-cell lung cancer1.18 (0.95–1.45)n = 547VOYAGERProgression-free survival (primary) · Sarcomas (sof…1.25 (0.99–1.57)n = 476MARS 2Overall survival (primary) · Mesothelioma1.28 (1.02–1.6)n = 335ASPREE (ASPirin in Redu…Other time-to-event · 1.31 (1.1–1.56)n = 19,114LACC (Laparoscopic Appr…Disease-free survival (primary) · Cervical cancer3.74 (1.63–8.58)n = 631
Download
Evidence scoreweakmoderatestrongvery strongHazard ratios are as reported by each trial and are not adjusted to a common comparator; rows are not pooled.

How to read it

Each row is one endpoint from one trial, taken from the structured outcomes recorded in the corpus with the publication linked as its source. The square sits at the reported hazard ratio; its area grows with the number of participants in the arms (or the trial enrolment when arm sizes are not recorded), and its shade follows the trial's evidence score (phase, size, endpoint type, result, replication).

Trials are not pooled and hazard ratios are not adjusted: a ratio from a placebo-controlled adjuvant trial is not directly comparable with one against an active comparator in the metastatic setting. Use the setting and endpoint filters to keep like with like, and open the trial page for the population, comparator and follow-up behind each number.